MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 573168 | Name: Antazoline phosphate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Antazoline phosphate is an antihistamine with anticholinergic properties used to relieve nasal congestion and the symptoms of allergic conjunctivitis. Antazoline is an ethylenediamine derivative with histamine H1 antagonistic and sedative properties. Antazoline antagonizes histamine H1 receptor and prevents the typical allergic symptoms caused by histamine activities on capillaries, skin, mucous membranes, and gastrointestinal and bronchial smooth muscles.

Chemical Structure

Antazoline phosphate
Antazoline phosphate
CAS#154-68-7 (phosphate)

Theoretical Analysis

MedKoo Cat#: 573168

Name: Antazoline phosphate

CAS#: 154-68-7 (phosphate)

Chemical Formula: C17H22N3O4P

Exact Mass: 363.1348

Molecular Weight: 363.35

Elemental Analysis: C, 56.20; H, 6.10; N, 11.56; O, 17.61; P, 8.52

Price and Availability

Size Price Availability Quantity
500mg USD 500.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
154-68-7 (phosphate) 91-75-8 (free base) 2508-72-7 (HCl) 3131-32-6 (mesylate) 24359-81-7 (sulfate) 145178-44-5 (nitrate)
Synonym
Antazoline phosphate
IUPAC/Chemical Name
N-Benzyl-4,5-dihydro-N-phenyl-1H-imidazole-2-methylamine monophosphate
InChi Key
DUIGUKRYYAGJAF-UHFFFAOYSA-N
InChi Code
1S/C17H19N3.H3O4P/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16;1-5(2,3)4/h1-10H,11-14H2,(H,18,19);(H3,1,2,3,4)
SMILES Code
c1ccc(cc1)CN(CC2=NCCN2)c3ccccc3.OP(=O)(O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 363.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Calvert P, Gupta D, Lip GYH. Antazoline: the Lazarus of antiarrhythmic drugs? Pol Arch Intern Med. 2022 Jun 29;132(6):16264. doi: 10.20452/pamw.16264. Epub 2022 Jun 29. PMID: 35766936. 2: Wybraniec MT, Wróbel W, Wilkosz K, Wrona K, Bula K, Mizia-Stec K. Pharmacological Cardioversion With Antazoline in Atrial Fibrillation: The Results of the CANT Study. J Am Heart Assoc. 2018 Oct 16;7(20):e010153. doi: 10.1161/JAHA.118.010153. PMID: 30371270; PMCID: PMC6474954. 3: Ellermann C, Sterneberg M, Kochhäuser S, Dechering DG, Fehr M, Eckardt L, Frommeyer G. Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes. Europace. 2018 Oct 1;20(10):1699-1706. doi: 10.1093/europace/eux383. PMID: 29377987. 4: Lévy S. Cardioversion of recent-onset atrial fibrillation using intravenous antiarrhythmics: A European perspective. J Cardiovasc Electrophysiol. 2021 Dec;32(12):3259-3269. doi: 10.1111/jce.15264. Epub 2021 Oct 25. PMID: 34662471. 5: Farkowski MM, Maciag A, Kowalik I, Konka M, Szwed H, Pytkowski M. Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venous conduction and high clinical effectiveness (AntaEP Study). Br J Clin Pharmacol. 2019 Jul;85(7):1552-1558. doi: 10.1111/bcp.13940. Epub 2019 May 23. PMID: 30920001; PMCID: PMC6595364. 6: Balsam P, Koźluk E, Peller M, Piątkowska A, Lodziński P, Kiliszek M, Kołtowski Ł, Grabowski M, Opolski G. Antazoline for termination of atrial fibrillation during the procedure of pulmonary veins isolation. Adv Med Sci. 2015 Sep;60(2):231-5. doi: 10.1016/j.advms.2015.03.002. Epub 2015 Apr 1. PMID: 25919055. 7: Bińkowski BJ, Makowski M, Kubiński P, Lubiński A. Effect of Antazoline on Electrophysiological Properties of Atrial Muscle and Conduction System of the Heart. Cardiovasc Drugs Ther. 2018 Apr;32(2):169-173. doi: 10.1007/s10557-018-6787-9. PMID: 29623481; PMCID: PMC5958171. 8: Wybraniec MT, Maciąg A, Miśkowiec D, Ceynowa-Sielawko B, Balsam P, Wójcik M, Wróbel W, Farkowski M, Ćwiek-Rębowska E, Szołkiewicz M, Ozierański K, Błaszczyk R, Bula K, Dembowski T, Peller M, Krzowski B, Wańha W, Koziński M, Kasprzak JD, Szwed H, Mizia-Stec K. Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study). Pol Arch Intern Med. 2022 Jun 29;132(6):16234. doi: 10.20452/pamw.16234. Epub 2022 Mar 16. PMID: 35293200. 9: Swiader M, Wielosz M, Czuczwar SJ. Influence of antazoline and ketotifen on the anticonvulsant activity of conventional antiepileptics against maximal electroshock in mice. Eur Neuropsychopharmacol. 2004 Aug;14(4):307-18. doi: 10.1016/j.euroneuro.2003.09.005. PMID: 15163441. 10: Piotrowski R, Giebułtowicz J, Baran J, Sikorska A, Gralak-Łachowska D, Soszyńska M, Wroczyński P, Kułakowski P. Antazoline-insights into drug-induced electrocardiographic and hemodynamic effects: Results of the ELEPHANT II substudy. Ann Noninvasive Electrocardiol. 2017 Sep;22(5):e12441. doi: 10.1111/anec.12441. Epub 2017 Feb 25. PMID: 28236352; PMCID: PMC6931461. 11: Maciag A, Farkowski MM, Chwyczko T, Beckowski M, Syska P, Kowalik I, Pytkowski M, Wozniak J, Dabrowski R, Szwed H. Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study). Europace. 2017 Oct 1;19(10):1637-1642. doi: 10.1093/europace/euw384. PMID: 28339554. 12: Wiśniowska B, Giebułtowicz J, Piotrowski R, Kułakowski P, Polak S. Development and Performance Verification of the PBPK Model for Antazoline and Its Metabolite and Its Utilization for Pharmacological Hypotheses Formulating. Pharmaceuticals (Basel). 2022 Mar 20;15(3):379. doi: 10.3390/ph15030379. PMID: 35337175; PMCID: PMC8953460. 13: Farkowski MM, Maciąg A, Żurawska M, Pytkowski M, Kowalik I, Woźniak J, Sterliński M, Szwed H. Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department. Pol Arch Med Wewn. 2016 Jun 24;126(6):381-7. doi: 10.20452/pamw.3452. Epub 2016 Jun 24. PMID: 27362390. 14: Miller J, Wolf EH. Antazoline phosphate and naphazoline hydrochloride, singly and in combination for the treatment of allergic conjunctivitis-a controlled, double-blind clinical trial. Ann Allergy. 1975 Aug;35(2):81-6. PMID: 1096685. 15: Piotrowski R, Kryński T, Baran J, Futyma P, Stec S, Kułakowski P. Antazoline for rapid termination of atrial fibrillation during ablation of accessory pathways. Cardiol J. 2014;21(3):299-303. doi: 10.5603/CJ.a2013.0121. Epub 2013 Aug 30. PMID: 23990192. 16: Souri E, Amanlou M, Farsam H, Afshari A. A rapid derivative spectrophotometric method for simultaneous determination of naphazoline and antazoline in eye drops. Chem Pharm Bull (Tokyo). 2006 Jan;54(1):119-22. doi: 10.1248/cpb.54.119. PMID: 16394564. 17: Farkowski MM, Maciąg A, Żurawska M, Kołakowski K, Gardziejczyk P, Kowalik I, Szwed H, Pytkowski M. Rapid pharmacological cardioversion of recent-onset atrial fibrillation using antazoline in elderly patients. Pol Arch Intern Med. 2022 Jan 28;132(1):16120. doi: 10.20452/pamw.16120. Epub 2021 Oct 13. PMID: 34643078. 18: Thomseth V, Cejvanovic V, Jimenez-Solem E, Poulsen HE, Utheim TP, Andersen JT. Exposure to antazoline-naphazoline eye drops during pregnancy and the risk of congenital malformations: a Danish nationwide cohort study. Acta Ophthalmol. 2019 Aug;97(5):505-509. doi: 10.1111/aos.13980. Epub 2018 Nov 26. PMID: 30479070. 19: Li J, Hu Y, Yuan Y, Zhao Y, Han Q, Liu C, Hu X, Zhou Y, Wang Y, Guo Y, Wu C, Chen X, Pei R. Repurposing of Antazoline Hydrochloride as an Inhibitor of Hepatitis B Virus DNA Secretion. Virol Sin. 2021 Jun;36(3):501-509. doi: 10.1007/s12250-020-00306-2. Epub 2020 Nov 9. PMID: 33165771; PMCID: PMC8257819. 20: Giebułtowicz J, Piotrowski R, Baran J, Kułakowski P, Wroczyński P. Application of a novel liquid chromatography/tandem mass spectrometry method for the determination of antazoline in human plasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokinetic and hemodynamic effects of PHenazolinum (ANTazoline mesylate)] human pharmacokinetic study. J Pharm Biomed Anal. 2016 May 10;123:113-9. doi: 10.1016/j.jpba.2016.01.060. Epub 2016 Feb 1. PMID: 26895496.